JW THERAP-B (02126) Income Statement & Earnings

2.220
-0.140-5.93%

Market Closed May 15 16:01 CST

925.14MMarket Cap-1.51P/E (TTM)

JW THERAP-B (02126) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

79.28%283.65M

22.50%106.35M

-8.99%158.22M

-1.05%86.82M

19.32%173.86M

32.93%87.74M

373.10%145.7M

--66.01M

--30.8M

----

Operating income

79.28%283.65M

22.50%106.35M

-8.99%158.22M

-1.05%86.82M

19.32%173.86M

32.93%87.74M

373.10%145.7M

66.01M

30.8M

Cost of sales

-36.67%-110.57M

4.27%-41.23M

5.53%-80.9M

-0.33%-43.07M

1.51%-85.64M

-0.12%-42.93M

-299.71%-86.95M

---42.88M

---21.75M

----

Operating expenses

-36.67%-110.57M

4.27%-41.23M

5.53%-80.9M

-0.33%-43.07M

1.51%-85.64M

-0.12%-42.93M

-299.71%-86.95M

-42.88M

-21.75M

Gross profit

123.86%173.08M

48.86%65.12M

-12.36%77.32M

-2.38%43.75M

50.14%88.22M

93.74%44.81M

549.60%58.76M

23.13M

9.05M

Selling expenses

-9.92%-154.35M

23.21%-58.49M

-24.04%-140.41M

-26.60%-76.17M

40.70%-113.2M

28.75%-60.17M

-11.80%-190.88M

-82.88%-84.45M

-1,186.80%-170.73M

---46.18M

Administrative expenses

34.63%-78.49M

45.66%-32.19M

14.27%-120.07M

24.73%-59.23M

22.09%-140.05M

13.45%-78.69M

10.80%-179.76M

13.49%-90.92M

12.87%-201.52M

-29.74%-105.1M

Research and development expenses

33.43%-188.38M

39.05%-92.04M

31.58%-282.99M

30.26%-151.01M

-1.42%-413.62M

-10.54%-216.53M

1.59%-407.82M

-5.59%-195.89M

-84.00%-414.4M

-125.50%-185.51M

Special items of operating profit

-122.93%-313.61M

-3,116.39%-155.83M

33.32%-140.68M

93.89%-4.85M

-54.92%-210.97M

5.36%-79.34M

-835.36%-136.18M

-2,713.15%-83.83M

-36.01%18.52M

-35.35%3.21M

Operating profit

7.43%-561.75M

-10.48%-273.44M

23.15%-606.84M

36.52%-247.51M

7.74%-789.61M

9.73%-389.92M

-12.75%-855.88M

-29.49%-431.96M

-72.19%-759.08M

-110.71%-333.58M

Financing income

-26.30%20.96M

-6.59%12.42M

-16.44%28.43M

-11.86%13.3M

105.78%34.03M

179.41%15.09M

99.31%16.54M

179.21%5.4M

141.09%8.3M

1,434.92%1.93M

Financing cost

6.43%-11.43M

-3.19%-6.25M

1.57%-12.22M

-8.42%-6.05M

-82.92%-12.42M

-106.85%-5.58M

-152.12%-6.79M

-402.61%-2.7M

-249.61%-2.69M

-85.17%-537K

Special items of earning before tax

----

104.17%51.15M

110.47%51.49M

Earning before tax

6.50%-552.23M

-11.24%-267.27M

23.10%-590.62M

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

Tax

---3.07M

----

After-tax profit from continuing operations

5.98%-555.29M

-11.24%-267.27M

23.10%-590.62M

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

Earning after tax

5.98%-555.29M

-11.24%-267.27M

23.10%-590.62M

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

Profit attributable to shareholders

5.98%-555.29M

-11.24%-267.27M

23.10%-590.62M

36.84%-240.27M

9.23%-768M

11.38%-380.42M

-20.48%-846.14M

-52.93%-429.25M

57.79%-702.33M

56.82%-280.7M

Basic earnings per share

6.29%-1.34

-10.34%-0.64

23.53%-1.43

37.63%-0.58

9.22%-1.87

11.43%-0.93

-17.05%-2.06

-47.89%-1.05

86.04%-1.76

92.87%-0.71

Diluted earnings per share

6.29%-1.34

-10.34%-0.64

23.53%-1.43

37.63%-0.58

9.22%-1.87

11.43%-0.93

-17.05%-2.06

-47.89%-1.05

86.04%-1.76

92.87%-0.71

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Deloitte Touche Tohmatsu会计师事务所

PwC

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	79.28%283.65M	22.50%106.35M	-8.99%158.22M	-1.05%86.82M	19.32%173.86M	32.93%87.74M	373.10%145.7M	--66.01M	--30.8M	----
Operating income	79.28%283.65M	22.50%106.35M	-8.99%158.22M	-1.05%86.82M	19.32%173.86M	32.93%87.74M	373.10%145.7M	66.01M	30.8M
Cost of sales	-36.67%-110.57M	4.27%-41.23M	5.53%-80.9M	-0.33%-43.07M	1.51%-85.64M	-0.12%-42.93M	-299.71%-86.95M	---42.88M	---21.75M	----
Operating expenses	-36.67%-110.57M	4.27%-41.23M	5.53%-80.9M	-0.33%-43.07M	1.51%-85.64M	-0.12%-42.93M	-299.71%-86.95M	-42.88M	-21.75M
Gross profit	123.86%173.08M	48.86%65.12M	-12.36%77.32M	-2.38%43.75M	50.14%88.22M	93.74%44.81M	549.60%58.76M	23.13M	9.05M
Selling expenses	-9.92%-154.35M	23.21%-58.49M	-24.04%-140.41M	-26.60%-76.17M	40.70%-113.2M	28.75%-60.17M	-11.80%-190.88M	-82.88%-84.45M	-1,186.80%-170.73M	---46.18M
Administrative expenses	34.63%-78.49M	45.66%-32.19M	14.27%-120.07M	24.73%-59.23M	22.09%-140.05M	13.45%-78.69M	10.80%-179.76M	13.49%-90.92M	12.87%-201.52M	-29.74%-105.1M
Research and development expenses	33.43%-188.38M	39.05%-92.04M	31.58%-282.99M	30.26%-151.01M	-1.42%-413.62M	-10.54%-216.53M	1.59%-407.82M	-5.59%-195.89M	-84.00%-414.4M	-125.50%-185.51M
Special items of operating profit	-122.93%-313.61M	-3,116.39%-155.83M	33.32%-140.68M	93.89%-4.85M	-54.92%-210.97M	5.36%-79.34M	-835.36%-136.18M	-2,713.15%-83.83M	-36.01%18.52M	-35.35%3.21M
Operating profit	7.43%-561.75M	-10.48%-273.44M	23.15%-606.84M	36.52%-247.51M	7.74%-789.61M	9.73%-389.92M	-12.75%-855.88M	-29.49%-431.96M	-72.19%-759.08M	-110.71%-333.58M
Financing income	-26.30%20.96M	-6.59%12.42M	-16.44%28.43M	-11.86%13.3M	105.78%34.03M	179.41%15.09M	99.31%16.54M	179.21%5.4M	141.09%8.3M	1,434.92%1.93M
Financing cost	6.43%-11.43M	-3.19%-6.25M	1.57%-12.22M	-8.42%-6.05M	-82.92%-12.42M	-106.85%-5.58M	-152.12%-6.79M	-402.61%-2.7M	-249.61%-2.69M	-85.17%-537K
Special items of earning before tax	----	----	----	----	----	----	----	----	104.17%51.15M	110.47%51.49M
Earning before tax	6.50%-552.23M	-11.24%-267.27M	23.10%-590.62M	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M
Tax	---3.07M	----	----	----	----	----	----	----	----	----
After-tax profit from continuing operations	5.98%-555.29M	-11.24%-267.27M	23.10%-590.62M	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M
Earning after tax	5.98%-555.29M	-11.24%-267.27M	23.10%-590.62M	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M
Profit attributable to shareholders	5.98%-555.29M	-11.24%-267.27M	23.10%-590.62M	36.84%-240.27M	9.23%-768M	11.38%-380.42M	-20.48%-846.14M	-52.93%-429.25M	57.79%-702.33M	56.82%-280.7M
Basic earnings per share	6.29%-1.34	-10.34%-0.64	23.53%-1.43	37.63%-0.58	9.22%-1.87	11.43%-0.93	-17.05%-2.06	-47.89%-1.05	86.04%-1.76	92.87%-0.71
Diluted earnings per share	6.29%-1.34	-10.34%-0.64	23.53%-1.43	37.63%-0.58	9.22%-1.87	11.43%-0.93	-17.05%-2.06	-47.89%-1.05	86.04%-1.76	92.87%-0.71
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--
Auditor	Deloitte Touche Tohmatsu会计师事务所	--	Deloitte Touche Tohmatsu会计师事务所	--	PwC	--	PwC	--	PwC	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"